CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death

Archive ouverte

Lévy, Yves | Wiedemann, Aurélie | Hejblum, Boris P. | Durand, Mélany | Lefebvre, Cécile | Surénaud, Mathieu | Lacabaratz, Christine | Perreau, Matthieu | Foucat, Emile | Déchenaud, Marie | Tisserand, Pascaline | Blengio, Fabiola | Hivert, Benjamin | Gauthier, Marine | Cervantes-Gonzalez, Minerva | Bachelet, Delphine | Laouénan, Cédric | Bouadma, Lila | Timsit, Jean-François | Yazdanpanah, Yazdan | Pantaleo, Giuseppe | Hocini, Hakim | Thiébaut, Rodolphe

Edité par CCSD ; Elsevier -

International audience. The identification of patients with coronavirus disease 2019 and high risk of severe disease is a challenge in routine care. We performed cell phenotypic, serum, and RNA sequencing gene expression analyses in severe hospitalized patients (n = 61). Relative to healthy donors, results showed abnormalities of 27 cell populations and an elevation of 42 cytokines, neutrophil chemo-attractants, and inflammatory components in patients. Supervised and unsupervised analyses revealed a high abundance of CD177, a specific neutrophil activation marker, contributing to the clustering of severe patients. Gene abundance correlated with high serum levels of CD177 in severe patients. Higher levels were confirmed in a second cohort and in intensive care unit (ICU) than non-ICU patients (P < 0.001). Longitudinal measurements discriminated between patients with the worst prognosis, leading to death, and those who recovered (P = 0.01). These results highlight neutrophil activation as a hallmark of severe disease and CD177 assessment as a reliable prognostic marker for routine care.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion